Major companies in the Uveitis Drug Market include AbbVie Inc., Novartis AG, Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., and Clearside Biomedical, Inc.
In August 2021, AbbVie launched a new formulation of Adalimumab (Humira) for non-infectious intermediate, posterior, and panuveitis.
In October 2022, Novartis introduced Beovu (brolucizumab) for uveitic macular edema in selected markets.
In May 2023, Clearside Biomedical announced the U.S. FDA approval of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of uveitis-related complications.
Bausch + Lomb expanded its intraocular corticosteroid portfolio through strategic acquisitions and partnerships in 2024.
The countries covered in the Uveitis Drug Market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.